co-diagnostics
-
Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Hepatitis C Viral Load Test
Co-Diagnostics announced that CoSara Diagnostics has received clearance by the CDSCO in India to manufacture and sell its…
-
Co-Diagnostics Reports Full Year 2021 Financial Results
Achieved Record Full Year Revenue of $97.9 Million; Strength in Sales Momentum Provides Foundation to Achieve Solid FY’22
-
Co-Diagnostics, Inc. Makes Strategic Additions to Scientific Advisory Board
Co-Diagnostics, Inc. Makes Strategic Additions to Scientific Advisory Board
-
Co-Diagnostics, Inc. Announces Authorization of $30 Million Share Repurchase Program
Co-Diagnostics announced that its Board of Directors has authorized a share repurchase program that would allow the Company…
-
Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Hepatitis B Viral Load Test
SALT LAKE CITY, Feb. 3, 2022 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with…
-
Co-Diagnostics, Inc. to Host Booth at Life Sciences Day on the Hill on February 16 at the Utah State Capital
Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development…
-
Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for High-Risk HPV Multiplex Test
Co-Diagnostics, Inc. announced that CoSara Diagnostics Pvt Ltd has received clearance by the Central Drugs Standard Control Organization (“CDSCO”)…
-
Co-Diagnostics, Inc. Signs Agreement to Acquire all Assets and Intellectual Property Related to At-Home/Point-of-Care Platform
Definitive merger agreements provide the Company with all existing and future assets, future product iterations, and intellectual property…
-
Co-Diagnostics JV CoSara Receives Clearance from Indian Regulators for ABC Multiplex Test
Co-Diagnostics announced that CoSara Diagnostics Pvt Ltd has received clearance by the Central Drugs Standard Control Organization (CDSCO)…
-
Co-Diagnostics, Inc. Reports that Suite of COVID-19 Diagnostics Not Affected by Heavily Mutated Omicron Variant
None of the mutations in the Omicron variant interfere with any of the Company’s COVID-19 PCR diagnostic assays
-
Co-Diagnostics Reports Continued Strength in Third Quarter 2021 Financial Results
Solid quarterly results highlighted by record revenue of $30.1 million, pre-tax income of $13.6 million and fully diluted…
-
Co-Diagnostics, Inc. Logix Smart™ COVID-19 2-Gene Test Approved for Use in the United Kingdom
Company’s validated test available in the UK following implementation of UKHSA CTDA Regulations
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- chair
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
